Methods	Multicentre, randomised, double-blind, placebo-controlled, parallel-group. Single dose to treat single attack Medication administered when migraine headache pain was of moderate or severe intensity Assessments at 30, 60, and 120 minutes after dosing An open 3 mg injection of sumatriptan was available after 30 minutes if headache had not improved to no worse than mild Rescue medication (not containing ergotamine or dihydroergotamine) was available after 60 minutes if relief remained inadequate
Participants	Aged 18 to 60 years, meeting IHS criteria for migraine (1988) with or without aura. At least 1-year history of migraine (untreated severity ≥ moderate) with 1 to 6 attacks per month No use of ergotamine or morphine-containing preparations within 24 h, or analgesics within 6 h of study treatment The use of prophylactic therapy, provided it did not contain ergotamine, was allowed N = 685 (672 for efficacy) M 165, F 520 (76%) Mean age 40 years Without aura 76%
Interventions	Sumatriptan 1 mg, n = 170 Sumatriptan 2 mg, n = 171 Sumatriptan 3 mg, n = 172 Placebo, n = 172
Outcomes	Efficacy data only reported for 30 minutes Adverse events Withdrawals
Notes	Oxford Quality Score: R1, DB1, W1. Total = 3.
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported
Study size	Unclear risk	Treatment groups 50 to 200 participants